Endoscopy in Barrett's esophagus: Surveillance during reflux management and new advances in the diagnosis and early detection of dysplasia

Chest Surgery Clinics of North America

Volumn 12, Issue 1, 2002, Pages 47-58

  Elkhoury, Jihad ^a   Sahai, Anand V ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; METHYLENE BLUE; MUCOLYTIC AGENT; PORPHYRIN DERIVATIVE; PROTOPORPHYRIN; TUMOR MARKER;

BARRETT ESOPHAGUS; CYTOLOGY; DIAGNOSTIC ACCURACY; DYSPLASIA; ECHOGRAPHY; ENDOSCOPIC BIOPSY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; FLUORESCENCE; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SPECTROMETRY;

EID: 0036190951     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1052-3359(03)00065-6     Document Type: Review

References (62)

1. High-resolution endoluminal sonography is a sensitive modality for the identification of Barrett's metaplasia
2. Usefulness of cytopathology and histology in the evaluation of Barrett's esophagus in a community hospital
3. The role of endoscopy in the surveillance of premalignant condition of the upper gastrointestinal tract
4. Endoscopic ultraviolet-induced autofluorescence spectroscopy of the esophagus: Tissue characterization and potential for early cancer diagnosis
5. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study
6. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus
7. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus
8. Methylene blue staining: Is it really useful in Barrett's esophagus?
9. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years
10. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting
11. Endoscopic fluorescence detection of low and high grade dysplasia in Barrett's oesophagus using systemic or local 5-amino-laevulinic acid sensitisation
12. Barrett's esophagus
13. Endoscopic surveillance of Barrett's esophagus: Risk stratification and cancer risk
14. Endosonography in the evaluation of patients with Barrett's esophagus and high-grade dysplasia
15. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology
16. Practice patterns for surveillance of Barrett's esophagus in the United States
17. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia
18. Methylene blue staining and endoscopic ultrasound evaluation of Barrett's esophagus with low-grade dysplasia
19. The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus
20. Management of Barrett's esophagus: A national study of practice patterns and their cost implications
21. Brush cytology in the diagnosis of neoplasia in Barrett's esophagus
22. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma
23. In vivo endoscopic optical coherence tomography of esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus
24. Screening for specialized columnar epithelium with methylene blue: Chromoendoscopy in patients with Barrett's esophagus and a normal control group
25. High-resolution cross-sectional imaging of the gastrointestinal tract using optical coherence tomography: Preliminary results
26. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
27. Optical coherence tomography: Advanced technology for the endoscopic imaging of Barrett's esophagus
28. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: Observational study
29. Endoscopic photodynamic diagnosis: Oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions
30. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus
31. 5-Aminolevulinic acid-induced protoporphyrin IX for the detection of gastrointestinal dysplasia
32. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization
33. Rapid acquisition of multiple biopsies using a suction assisted multi-biopsy device (SAMD): Blinded comparison with radial jaw forceps (RJ) in a porcine model
34. Barrett's esophagus: Update on screening, surveillance, and treatment
35. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry
36. The economic impact of the diagnosis of dysplasia in Barrett's esophagus
37. Spectroscopic diagnosis of esophageal cancer: New classification model, improved measurement system
38. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus
39. Feasibility of optical coherence tomography for high-resolution imaging of human gastrointestinal tract malignancies
40. Diagnosis of specialized intestinal metaplasia by optical coherence tomography
41. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk
42. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort
43. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions
44. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus
45. Biomarkers for malignancy in the columnar-lined esophagus
46. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
47. High-resolution endoscopic imaging of the GI tract using optical coherence tomography
48. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
49. Surveillance for Barrett's oesophagus in the UK
50. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost-effective?
51. Endoscopic ultrasound in the evaluation of Barrett's esophagus: A preliminary report
52. In vivo endoscopic optical biopsy with optical coherence tomography
53. Optical biopsy in human gastrointestinal tissue using optical coherence tomography
54. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus
55. Surveillance of Barrett's oesophagus: Physicians' practices and review of current guidelines
56. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma
57. Barrett's mucosa, Barrett's dysplasia and Barrett's carcinoma: Diagnostic endoscopy without biopsy-taking does not suffice
58. Laser-induced fluorescence for esophageal cancer and dysplasia diagnosis
59. Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence
60. Endoscopic detection of dysplasia in patients with Barrett's esophagus using light-scattering spectroscopy
61. Value of cytology in detecting intestinal metaplasia and associated dysplasia at the gastroesophageal junction
62. Predicting who will develop cancer: Role of biopsy, flow cytometry, cell and genetic markers